首页 | 本学科首页   官方微博 | 高级检索  
     

注射用重组人TNK组织型纤溶酶原激活剂溶栓治疗急性ST段抬高型心肌梗死的效果
引用本文:陈培开. 注射用重组人TNK组织型纤溶酶原激活剂溶栓治疗急性ST段抬高型心肌梗死的效果[J]. 中国现代药物应用, 2022, 0(3): 129-131
作者姓名:陈培开
作者单位:广州市南沙区第六人民医院
摘    要:目的 探析注射用重组人TNK组织型纤溶酶原激活剂(rhTNK-tPA)溶栓治疗急性ST段抬高型心肌梗死的效果.方法 32例急性ST段抬高型心肌梗死患者作为研究对象,以治疗方式的不同分为参照组及研究组,每组16例.参照组应用尿激酶治疗,研究组应用rhTNK-tPA治疗.对比两组溶栓治疗后90 min行冠状动脉造影患者的冠...

关 键 词:注射用重组人TNK组织型纤溶酶原激活剂  急性ST段抬高型心肌梗死  尿激酶

Effect of thrombolysis with recombinant human TNK tissue plasminogen activator for injection in the treatment of acute ST-segment elevation myocardial infarction
CHEN Pei-kai. Effect of thrombolysis with recombinant human TNK tissue plasminogen activator for injection in the treatment of acute ST-segment elevation myocardial infarction[J]. Chinese Journal of Modern Drug Application, 2022, 0(3): 129-131
Authors:CHEN Pei-kai
Affiliation:(Sixth People’s Hospital of Nansha District,Guangzhou 511470,China)
Abstract:Objective To discuss the effect of thrombolysis with recombinant human TNK tissue plasminogen activator(rhTNK-tPA)for injection in the treatment of acute ST-segment elevation myocardial infarction.Methods A total of 32 patients with acute ST-segment elevation myocardial infarction were studied and divided into reference group and research group according to different treatment methods,with 16 cases in each group.The control group was treated with urokinase,and the research group was treated with rhTNKtPA.The coronary angiography results of patients with coronary angiography at 90 min after thrombolytic therapy,incidence of endpoint events after thrombolytic therapy,and revascularization rate of patients without coronary angiography at 90 min after thrombolytic therapy were compared between the two groups.Results The recanalization rates of infarct-related vessels(IRA)thrombolysis in myocardial infarction(TIMI)grade 3 and IRA TIMI grade 2-3 in the research group were 83.33%and 91.67%in patients undergoing coronary angiography at 90 min after thrombolytic therapy,which were higher than 38.46%and 46.15%in the reference group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidences of death(within 30 d),target vessel reconstruction,myocardial ischemia recurrence,cardiogenic shock,reinfarction,and other complications between the two groups after thrombolytic therapy(P>0.05).There was no statistically significant difference in the revascularization rate between the two groups of patients without coronary angiography at 90 min after thrombolytic therapy(P>0.05).Conclusion The application of rhTNK-tPA in patients with acute ST-segment elevation myocardial infarction can improve the recanalization rate of coronary angiography with certain safety.
Keywords:Recombinant human TNK tissue plasminogen activator for injection  Acute ST-segment elevation myocardial infarction  Urokinase
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号